secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001140361-24-036283
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore reports Q2 2024 revenue growth of 32% driven by KIMMTRAK sales of $75.3 million
--------------------------------------------------------------------------------

- KIMMTRAK net revenues were $75.3 million in Q2 2024, up 32% year-over-year, driven by US growth and global expansion.
- Registrational Phase 3 TEBE-AM trial for KIMMTRAK in cutaneous melanoma converted from Phase 2/3; enrollment completion expected in 1H 2026.
- First patient randomized in Phase 3 PRISM-MEL-301 trial evaluating brenetafusp + nivolumab in first-line cutaneous melanoma.
- Cash and equivalents at $859.6 million; company plans to repay $50 million loan by end of 2024.
- Net loss narrowed to $11.6 million from $17.0 million in prior year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124036283/0001140361-24-036283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124036283/ef20033789_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer